Basic study on new treatment strategy targeting mevalonate pathway in prostate cancer

点击翻译按钮获取中文摘要

In this study, the therapeutic potential of statin and zoledoronic acid, mevalotate pathway targeting agents, was studied. Both agents inhibited prostate cancer cell proliferations, especially, statins specifically inhibited proliferation of PC-3, androgen-independent cells. Prostate cancer cells expressed LDL receptor. LNCAP cells had abilities to regulate expression of LDL receptor in response to exogeneous or endogenouse lipid levels. In contrast, PC-3 lacked this ability and statin exerts its antiproliferative effect in PC-3 cells. These results suggested that mevalonate targeting agents, such as statin and zoledoronic acid, have potentials to use for prostate cancer.